Insilico and SK Biopharmaceuticals Launch $2.5B AI Drug Partnership

Insilico Medicine has entered a collaboration with SK Biopharmaceuticals worth up to $2.5 billion to discover drug candidates for neuroimmune disorders affecting the central nervous system. The partnership pairs Insilico's AI-driven drug discovery platform with SK's clinical development expertise in CNS therapeutics.

Under the agreement, Insilico will deploy its Pharma.AI platform to discover, design, and optimize drug candidates against targets provided by SK. The platform addresses target validation, generative chemistry, and molecule optimization. SK Biopharmaceuticals will handle late-stage development and commercialization of resulting programs, according to details first reported by GEN.

Why it matters

This deal represents a shift from AI as experimental technology to production-level drug development tool. Neuroimmune disorders present significant technical challenges requiring molecules with brain penetration and high safety profiles—traditionally difficult properties to optimize simultaneously. The collaboration's scale and SK's willingness to bet on AI-designed molecules for one of medicine's most complex therapeutic areas signals growing pharmaceutical industry confidence in computational drug discovery.

Building on CNS expertise

SK Biopharmaceuticals brings established CNS credentials to the partnership. The South Korean biotech became the first Korean pharmaceutical company to independently develop and commercialize a novel drug in the United States with Xcopri (cenobamate), an epilepsy treatment approved by the FDA in 2019.

"This collaboration represents an important milestone in expanding our growth beyond epilepsy into new CNS therapeutic areas," said Donghoon Lee, SK Biopharmaceuticals' president and CEO. The company views the partnership as a scalable platform for future target discovery opportunities.

SK Biopharmaceuticals operates within SK Group, South Korea's second-largest conglomerate, whose holdings span vaccine development, contract manufacturing, and semiconductor production including AI processor components.

Insilico's expanding pipeline

Insilico maintains over 40 programs across therapeutic areas including cancer, metabolic diseases, and inflammatory conditions, with a strategic focus on aging-related targets. The company's most advanced candidate, rentosertib, targets idiopathic pulmonary fibrosis and has completed a Phase IIa trial in China with positive results published in Nature Medicine.

The company's pipeline includes ISM8969, a Phase I oral brain-penetrant NLRP3 inhibitor being co-developed with Hygtia Therapeutics for Parkinson's disease. The molecule demonstrated strong blood-brain barrier penetration and anti-inflammatory activity in preclinical studies.

Alex Zhavoronkov, Insilico's founder and co-CEO, emphasized the technical challenge ahead: "Neuroimmunology is a very difficult space, one of the most difficult disease areas to tackle, given the need to develop molecules with properties that include high levels of safety and brain penetration."

Second major deal of 2025

The SK partnership follows an up-to-$2.75 billion collaboration with Eli Lilly announced earlier this year. That agreement granted Lilly exclusive global rights to develop novel oral therapeutics in preclinical development, with $115 million paid upfront.

Zhavoronkov noted that AI "has transformed from being a fairy tale or a promise, to being a real tool that is used routinely to discover and develop drugs." He added: "This is basically production level. We're not trying to do a pilot here."

Details of the collaboration were first reported by GEN at the Biotechnology Innovation Organization International Convention in San Diego.